[2023. 10. 26.][NYSE:MCB]Metropolitan Commercial Bank Elevates Two Seasoned EB-5 Specialists to Co-Head the EB-5 Private Client Group

[2023. 10. 26.][NYSE:MCB]Metropolitan Commercial Bank Elevates Two Seasoned EB-5 Specialists to Co-Head the EB-5 Private Client Group

Metropolitan Commercial Bank Elevates Leadership in EB-5 Private Client Group

NEW YORK--(BUSINESS WIRE)-- Metropolitan Commercial Bank has announced the appointment of April Feely and James M. Sozomenou as Co-Heads of its EB-5 Private Client Group, reinforcing its commitment to providing tailored banking services for stakeholders in the USCIS EB-5 Immigrant Investor Program.

April Feely, a seasoned professional with 14 years of experience in EB-5 and E-2 client services at Signature Bank, brings her expertise to Metropolitan Commercial Bank. She is joined by James M. Sozomenou, who spent six years at Signature Bank, specializing in client development and operations for EB-5 and E-2 clients. Together, they are set to lead the team, serving the needs of investors, developers, Regional Centers, government agencies, law firms, and consulting companies specializing in EB-5 and E-2.

Mark R. DeFazio, President and CEO of Metropolitan Commercial Bank, commended both promotions, citing Feely's masterful expertise in EB-5 operations and Sozomenou's consistent delivery of exceptional results in the EB-5 market.

April Feely expressed her enthusiasm for this new chapter in her career and looks forward to expanding their relationships within the EB-5 community. She and James M. Sozomenou share excitement about the future, with the full support of Metropolitan Commercial Bank in ensuring the team's continued stellar reputation.

Metropolitan Commercial Bank, a New York City-based full-service commercial bank, is recognized for its global payments group's leadership in domestic and international fintech services. It provides a broad range of banking products and services to businesses, enterprises, municipalities, and individuals.

The bank's recent achievements include ranking among the top loan producers for 2023 and being recognized as one of the best-performing community banks in its asset category and region. It is committed to innovation and growth across the fintech and payments industry.

Metropolitan Commercial Bank continues to expand its presence and is poised for success in the EB-5 market under the leadership of April Feely and James M. Sozomenou.

For more information, please visit MCBankNY.com.

Forward-Looking Statement Disclaimer: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the bank's future financial performance and involve risks and uncertainties. The bank does not undertake any obligation to update or revise any forward-looking statement.

[2023. 10. 26.][NYSE:CYBN]Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

 [2023. 10. 26.][NYSE:CYBN]Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN), a trailblazing biopharmaceutical company in the field of mental healthcare, has just received a significant boost to its intellectual property portfolio with the grant of a new European patent. This patent, numbered 4,031,529, provides protection for Cybin's proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (DMT) programs.

This development underscores Cybin's commitment to advancing innovative psychedelic-based treatment options for mental health conditions. The newly granted European patent covers the composition of matter for specific deuterated tryptamine compounds, including deuterated psilocybin analogs within the CYB003 program and deuterated analogs of DMT within Cybin's DMT program, as well as their medical applications.

According to Doug Drysdale, Chief Executive Officer of Cybin, "Maintaining a secure intellectual property position is fundamental to our development strategy as we continue to advance our novel molecules and optimize their therapeutic benefits." With this European patent in place, Cybin's intellectual property protection around their deuterated DMT and deuterated psilocybin programs has been significantly reinforced.

Cybin's CYB003 program, focusing on deuterated psilocybin analogs, has already completed dosing in a Phase 2 trial for major depressive disorder (MDD). Interim findings have shown that CYB003 can produce a robust psychedelic response in participants at low doses while maintaining a safe and well-tolerated therapeutic profile.

Additionally, Cybin's proprietary deuterated DMT compounds, CYB004 and SPL028, are currently undergoing Phase I clinical trials. These compounds aim to extend the DMT psychedelic experience while keeping a short-duration drug profile, potentially enabling optimized dose formulations for various administration routes and delivering distinct therapeutic benefits for patients. Preliminary results indicate that intravenous CYB004 and SPL028 elicit a psychedelic experience lasting less than 1 hour and are well-tolerated.

The company anticipates reporting topline data from its deuterated psilocybin and DMT programs in the fourth quarter of 2023.

In terms of its broader mission, Cybin seeks to transform mental healthcare by developing safe and effective psychedelic-based therapeutics for individuals suffering from mental health conditions. The company collaborates with world-class partners and esteemed scientists to advance proprietary drug discovery platforms, innovative drug delivery systems, and novel treatment regimens. Cybin's research pipeline includes investigational psychedelic-based compounds such as CYB003 and CYB004.

With its headquarters in Canada and operations spanning across several countries, including the United States, the United Kingdom, the Netherlands, and Ireland, Cybin is poised to make a meaningful impact in the mental healthcare landscape.

[NASDAQ:TNXP]Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

 [NASDAQ:TNXP]Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is gearing up for a game-changing announcement in early December 2023 as they anticipate the release of topline results from their Phase 2 clinical trial. This trial is focused on TNX-1900, a novel formulation of intranasal oxytocin that incorporates magnesium (Mg2+), which has shown promising potential in animal models for enhancing the analgesic effects of oxytocin.

What sets TNX-1900 apart is its unique mechanism of action. It's designed to block the release of CGRP (calcitonin gene-related peptide), a key player in the pathogenesis of migraine headaches, from trigeminal ganglia neurons. This targeted approach aims to reduce systemic exposure while effectively combating chronic migraine, a condition that affects an estimated four million individuals in the U.S.

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated, "TNX-1900 is being developed as a novel, non-CGRP antagonist approach to treatment for chronic migraineurs." Despite the availability of several migraine preventives, there remains an unmet need for innovative treatments.

Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, expressed gratitude to the participants, their families, investigators, and researchers who contributed to the study's completion and eagerly awaits the results.

The Phase 2 PREVENTION study, a double-blind, randomized, placebo-controlled trial, evaluated the prophylactic use of TNX-1900 for chronic migraine prevention. It involved 88 participants across approximately 26 U.S. sites, and topline results will provide critical insights into the drug's efficacy and safety.

Migraine is a widespread neurological condition, affecting approximately 1.2 billion individuals globally, with 39 million sufferers in the U.S., including four million with chronic migraines. Current FDA-approved drugs for migraine prevention primarily include CGRP antagonists, but TNX-1900 offers a fresh and promising alternative.

TNX-1900's development as a non-CGRP antagonist is a potential game-changer in the migraine treatment landscape. The Phase 2 results, expected in early December, will be a significant milestone in Tonix Pharmaceuticals' quest to provide relief to those battling chronic migraines.

Intriguingly, TNX-1900's mechanism of action and potential applications extend beyond migraine treatment, including binge eating disorder, pediatric obesity, craniofacial pain conditions, and social anxiety disorder, showcasing its versatility in addressing various health challenges.

With the promise of innovation on the horizon, Tonix Pharmaceuticals is poised to make a meaningful impact on the lives of migraine sufferers and beyond.

[NYSE:IGT]IGT to Deliver Leading Lottery Solutions in Kentucky for 10 Additional Years

[NYSE:IGT]IGT to Deliver Leading Lottery Solutions in Kentucky for 10 Additional Years

IGT Extends Kentucky Lottery Contracts for 10 More Years

LONDON, Oct. 26, 2023 /PRNewswire/ -- International Game Technology PLC ("IGT") (NYSE: IGT) is set to continue its successful partnership with the Kentucky Lottery Corporation ("Kentucky Lottery") as it extends its two contracts until 2036. In a groundbreaking move, IGT will revamp the Kentucky Lottery's central system with its cutting-edge Aurora™ platform, supply state-of-the-art point-of-sale hardware to over 3,400 lottery retailers across Kentucky, and implement an upgraded iLottery system complete with cloud integration.

Mary R. Harville, President & CEO of the Kentucky Lottery Corporation, expressed her enthusiasm for the extended partnership, stating, "Enhancing our lottery solutions with IGT's retail and iLottery systems and convenient self-service retail terminals will provide more opportunities for us to responsibly grow our sales and return additional funds for scholarships and grants for Kentucky college students."

IGT's Chief Operating Officer Global Lottery, Jay Gendron, highlighted the importance of innovation, saying, "IGT's future-forward mindset and next-generation product portfolio are critical in today's evolving lottery space. Over the next 10 years, we will build upon our longstanding partnership with the Kentucky Lottery and deploy our sophisticated technology to further enhance the player experience."

Since 2016, IGT has collaborated with the Kentucky Lottery to expand its iLottery program, tripling the number of online draw games available to players and offering a diverse portfolio of eInstant games. The updated cloud-based iLottery platform will provide enhanced flexibility, analytics, and advanced player-management features, along with responsible gaming tools.

IGT's Aurora platform, part of its player-centric omnichannel solution OMNIA™, promises to bring innovation and profitability to the Kentucky Lottery. It will offer user-friendly applications, tools, and reporting capabilities, with components like Performance Wizard, Retailer Wizard, and Sales Wizard deployed to the cloud for optimal functionality. Additionally, IGT will deliver 4,000 new Retailer Pro terminals and ticket checkers, along with 850 GameTouch™ 28 lottery vending machines.

This extended partnership ensures that the Kentucky Lottery will receive IGT's upgraded iLottery system, complete with added security, dynamic scalability, and a streamlined system enhancement process. It will also facilitate faster integration of data and insights, enhancing the overall player experience and incorporating comprehensive responsible gaming features.

As a global leader in the lottery market, IGT continues to provide cutting-edge technology to numerous lotteries worldwide. With this contract extension, they solidify their position as a trusted partner in shaping the future of the Kentucky Lottery.

About IGT IGT (NYSE:IGT) is a global leader in gaming, delivering responsible and entertaining gaming experiences across all channels and regulated segments, from Lotteries and Gaming Machines to Sports Betting and Digital. With a strong commitment to innovation, player insights, and technological advancements, IGT creates unrivaled gaming experiences that engage players and drive growth. Operating in over 100 jurisdictions, IGT is known for its integrity, service standards, and value creation. For more information, visit www.igt.com.

Cautionary Statement Regarding Forward-Looking Statements This news release may contain forward-looking statements concerning International Game Technology PLC and its subsidiaries. These statements are based on current beliefs and assumptions, and actual results may differ due to various risks and uncertainties. The Company does not assume any obligation to update these forward-looking statements. For more information on risk factors, please refer to the Company's filings with the SEC.

Contact: Phil O'Shaughnessy, Global Communications, toll-free in U.S./Canada +1 (844) IGT-7452; outside U.S./Canada +1 (401) 392-7452 Francesco Luti, Italian media inquiries, +39 06 5189 9184 James Hurley, Investor Relations, +1 (401) 392-7190

© 2023 IGT

[2023.][NASDAQ:BCRX]BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

 [2023.][NASDAQ:BCRX]BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

In a groundbreaking development, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has initiated a proof-of-concept clinical trial for BCX10013, a potential game-changing oral Factor D inhibitor designed to treat complement-mediated diseases. The trial aims to evaluate the preliminary efficacy and safety profile of once-daily dosing with BCX10013.

Dr. Ryan Arnold, BioCryst's Chief Medical Officer, expressed the company's commitment to developing first-in-class or best-in-class medicines. BCX10013, with its potential for once-daily dosing and remarkable safety and efficacy, could revolutionize the treatment landscape for patients suffering from complement-mediated diseases like paroxysmal nocturnal hemoglobinuria (P**).

The trial, which is open-label and multicenter, will include up to 15 adult P** patients in countries where standard-of-care complement inhibitor therapy is unavailable. It will involve intra-subject dose escalation at four-week intervals, with treatment options lasting up to 24 weeks. The primary endpoints are focused on safety and include monitoring for treatment-emergent adverse events and laboratory abnormalities. Key secondary endpoints will assess efficacy through various biomarkers, such as lactate dehydrogenase (LDH) levels and hemoglobin levels.

BCX10013 is just one of BioCryst's initiatives in the field of complement system targeting. The company is actively developing medicines targeting different pathways within the complement system to address a range of complement-mediated diseases.

For more information about this groundbreaking trial, please visit ClinicalTrials.gov and search for NCT number NCT06100900.

About BioCryst Pharmaceuticals: BioCryst Pharmaceuticals specializes in discovering novel, oral, small-molecule medicines to treat rare diseases where significant unmet medical needs exist. Their flagship product, ORLADEYO® (berotralstat), is approved in the United States and several global markets. BioCryst continues to advance its complement program with BCX10013, an oral Factor D inhibitor in clinical development. Additionally, they have RAPIVAB® (peramivir injection) approved in the U.S. and multiple global markets.

Forward-Looking Statements: This press release includes forward-looking statements regarding BioCryst's complement program and future results. These statements are subject to various risks and uncertainties, including those related to the ongoing COVID-19 pandemic, delays in clinical development, regulatory challenges, and market acceptance of their products. For more information on these factors, please refer to BioCryst's recent filings with the Securities and Exchange Commission.

For further inquiries, please contact: John Bluth +1 919 859 7910 jbluth@biocryst.com

[NYSE:PERF]Perfect Corp. Unveils Unique Generative AI Technology for Hairstyling in YouCam Makeup App with World’s Most Advanced Virtual Try-On Solution

 [NYSE:PERF]Perfect Corp. Unveils Unique Generative AI Technology for Hairstyling in YouCam Makeup App with World’s Most Advanced Virtual Try-On Solution

Perfect Corp. Unveils Revolutionary Generative AI-Powered Hairstyling Experience in YouCam Makeup App

NEW YORK--(BUSINESS WIRE)-- Perfect Corp. (NYSE: PERF), the forefront AI and AR beauty tech solutions provider behind the popular YouCam suite of apps, is making waves in the beauty and hairstyling industry with its latest innovation. Today, the company announced the launch of its groundbreaking virtual try-on technology, driven by generative AI, within the YouCam Makeup app. This game-changing technology promises to redefine how users discover and experiment with hairstyles, offering the most advanced and realistic virtual try-on solution available in the market.

Harnessing Advanced Generative AI for Hairstyle Inspiration

Perfect Corp. leverages advanced generative AI models and stable diffusion techniques to create an extensive array of hyper-realistic hairstyles, colors, and textures. This ensures that users can effortlessly explore a wide range of hairstyles suitable for any occasion. As beauty enthusiasts increasingly seek personalized recommendations, Perfect Corp. has risen to the occasion, providing a solution to a common problem in the hairstyling space. Users can now visualize how trending hairstyles and hair lengths will complement their unique features in real-time, all thanks to the power of generative AI.

The Evolution from Generative Modeling to Precise Generative AI

Perfect Corp.'s latest virtual try-on solution for hairstyles marks a significant leap in hairstyling technology. It evolves from the traditional Generative Adversarial Network (GAN) technology to more sophisticated and precise generative AI models. Rather than offering generic hairstyle filters, this cutting-edge technology generates personalized hairstyle filters for each user. The use of generative AI guarantees lifelike, customized, and incredibly realistic representations of hairstyles on the user, empowering them to make confident decisions about their next hairstyle transformation.

Revolutionizing the Consumer Hairstyle Journey

Alice Chang, CEO, and Founder of Perfect Corp., expressed her excitement about this innovative technology, stating, "With Generative AI, we can simulate an endless array of hairstyles in real-time, helping consumers find the perfect look effortlessly. This technology is set to revolutionize the consumer experience while helping hair professionals and hair product brands provide more immersive and valuable consultations." Perfect Corp.'s commitment to pushing the boundaries of beauty technology continues to drive innovation in the industry.

To experience this new generative AI-powered hairstyle technology, download the YouCam Makeup app today.

About Perfect Corp.

Perfect Corp. (NYSE: PERF) leads the way in SaaS AI and AR beauty and fashion tech solutions, dedicated to transforming shopping experiences and empowering brands to thrive in the digital-first world. Partnering with industry giants, Perfect Corp. delivers technology-driven experiences that enable sustainable, ultra-personalized, and engaging shopping journeys. Perfect Corp. offers a suite of mobile apps, including YouCam Makeup and YouCam Perfect, providing consumers with a platform to virtually try on products, perform skin diagnoses, edit photos, and share experiences with the YouCam Community. To learn more, please visit PerfectCorp.com.

[NYSE:IHS]IHS Towers Partners with Limitless Space Institute to Inspire Space Exploration and Education in Brazil and Nigeria

 [NYSE:IHS]IHS Towers Partners with Limitless Space Institute to Inspire Space Exploration and Education in Brazil and Nigeria

NEW YORK & LONDON--(BUSINESS WIRE)-- In a groundbreaking move, IHS Holding Limited (NYSE: IHS) ("IHS Towers"), a global leader in shared communications infrastructure, is set to redefine the stock market landscape with its innovative partnership announcement. Starting in January 2024, the company will embark on a one-year collaboration with the Limitless Space Institute (LSI), a non-profit organization dedicated to space education and research.

Under this visionary partnership, IHS Towers will bring together 20 STEM educators from Brazil and Nigeria to participate in the Limitless Global Educator Program, a year-long initiative designed to revolutionize space education. These educators will gain access to an exclusive space education curriculum crafted by experts from the Limitless Space Institute.

The program will feature monthly virtual workshops, offering insights from renowned guest speakers in the field of space exploration and science. As a highlight, educators will also receive an invitation to attend the LSI Summer Institute in Houston, Texas, where they will immerse themselves in a week-long intensive program. Furthermore, representatives from the Limitless Space Institute will conduct in-person workshops in Brazil and Nigeria, providing educators with hands-on experiences that will undoubtedly ignite their passion for space education.

The selected educators will have access to a tailored curriculum covering a broad spectrum of topics, including the historical significance of space exploration, the underlying science, the economics of space, and the ethics of sustainable exploration. This comprehensive program aims to equip teachers with the tools and knowledge needed to inspire the next generation of students in the field of engineering and space exploration.

Applications for this life-changing opportunity open on November 1st, 2023, and can be submitted through the Limitless Space Institute website at https://www.limitlessspace.org/global-educators/. The application window will close on December 6th, 2023.

Sam Darwish, Chairman & CEO of IHS Towers, expressed his enthusiasm for the partnership, stating, "I am incredibly excited to announce our partnership with the Limitless Space Institute as we seek to continue strengthening education opportunities with a particular focus on increasing access to STEM subjects. Engineering excellence is IHS' lifeblood, and we could not be prouder to support the Limitless Space Institute's mission to equip educators globally with the resources and experiences they need to teach science and technology. We hope that by partnering with the Limitless Space Institute, we can contribute to bringing this exciting specialization to educators in Brazil and Nigeria, empowering them to spark a passion among their students on the wonders of engineering and space exploration."

Kaci Heins, Director of the Limitless Space Institute, added, "We are thrilled to collaborate with IHS Towers in our pursuit to elevate global STEM education. Our mission is not just to educate but to inspire the next generation to extend their exploration beyond our solar system. Educators and students are the heart of the future STEM workforce and space exploration. Equipped with the right resources, educators are poised to bring students to space-centric STEM disciplines. An energized educator lights the path for our future explorers. Space exploration, at its heart, stands for global unity and cooperation, which is pivotal for the collective advancement of humanity."

Marco Antonio Chamon, President of the Brazilian Space Agency, commended the initiative, stating, "I would like to congratulate IHS Towers and the Limitless Space Institute for their outstanding initiative in advancing STEM education on space-related topics for educators in both Brazil and Nigeria. It is crucial that space activities occupy a prominent position in the hearts and minds of the public, and education serves as the most direct way to accomplish this goal. The Brazilian Space Agency is proud to support this initiative in Brazil."

This partnership between IHS Towers and the Limitless Space Institute promises to be a game-changer in STEM education and space exploration, empowering educators to inspire and educate the next generation of space enthusiasts.

[2023. 10. 26.][NASDAQ:RNAZ]TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

 

[2023. 10. 26.][NASDAQ:RNAZ]TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Breakthrough in GBM Treatment

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- In a groundbreaking development, TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneer in RNA oncology, has unveiled a potential game-changer in the battle against glioblastoma multiforme (GBM). The company's lead therapeutic candidate, TTX-MC138, has demonstrated remarkable success in preclinical studies, offering newfound hope for patients battling this aggressive brain tumor.

GBM is a devastating disease with a high mortality rate, making any progress in its treatment a significant breakthrough. In a study led by Dr. Anna Moore of Michigan State University, TTX-MC138 was administered to mice with human GBM tumors as an alternative to the current standard-of-care chemotherapy, temozolomide (TMZ). TMZ resistance is a widespread problem in GBM treatment, contributing to its dismal survival rates.

The results are nothing short of remarkable. Mice treated with TTX-MC138 not only survived longer but also showed a remarkable increase in survival rates compared to the control group. At the 50-day mark after treatment initiation, an astonishing 75% of mice treated with TTX-MC138 were still alive, while only 25% of the control group had survived.

TransCode's Chief Technology Officer, Zdravka Medarova, PhD, emphasized the potential of TTX-MC138 to revolutionize GBM treatment, especially in cases where resistance to standard chemotherapy has developed.

TTX-MC138 is a unique therapy consisting of an iron oxide nanocarrier linked to a nucleic acid designed to inhibit microRNA-10b, a critical regulator of cancer progression in various advanced solid tumors, including GBM. The success of TTX-MC138 extends beyond GBM, with promising results in mouse models of pancreatic and breast cancer. Even in spontaneous feline mammary carcinoma, the therapy demonstrated efficacy.

Michael Dudley, Chief Executive Officer of TransCode, highlighted the significance of this breakthrough, stating, "Given the lethal nature of GBM, adding a therapeutic such as TTX-MC138 to the arsenal available to oncologists could potentially have a high impact on the future of GBM treatment."

TransCode has initiated a first-in-human clinical trial with TTX-MC138 for advanced solid cancers, aiming to quantify the therapy's delivery to metastatic lesions and assess its pharmacokinetics in cancer patients. Although this trial is not intended for therapeutic purposes, it holds promise for future clinical trials.

TransCode Therapeutics is on a mission to harness the potential of RNA therapeutics in the fight against cancer. With a portfolio of drug candidates targeting various tumor types, including breast, pancreatic, ovarian, colon, and glioblastomas, TransCode is at the forefront of innovative cancer treatments.

Forward-Looking Statements: This release contains forward-looking statements, and the actual results may differ due to various factors. Please refer to TransCode's Annual Report on Form 10-K for the year ended December 31, 2022, for a detailed discussion of potential risks and uncertainties.